ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 270 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65,021 | -13.0% | 3,120 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $74,724 | +126550.8% | 3,120 | 0.0% | 0.00% | – |
| Q1 2023 | $59 | +227.8% | 3,120 | +169.0% | 0.00% | – |
| Q4 2022 | $18 | -99.9% | 1,160 | +2.1% | 0.00% | – |
| Q3 2022 | $18,000 | -14.3% | 1,136 | -22.6% | 0.00% | – |
| Q2 2022 | $21,000 | -86.2% | 1,467 | -76.6% | 0.00% | -100.0% |
| Q1 2022 | $152,000 | -33.0% | 6,267 | -54.1% | 0.00% | 0.0% |
| Q3 2021 | $227,000 | -36.2% | 13,648 | -6.5% | 0.00% | -50.0% |
| Q2 2021 | $356,000 | +24.5% | 14,601 | +31.6% | 0.00% | 0.0% |
| Q1 2021 | $286,000 | -51.8% | 11,091 | 0.0% | 0.00% | -50.0% |
| Q4 2020 | $593,000 | +244.8% | 11,091 | +165.8% | 0.00% | +300.0% |
| Q3 2020 | $172,000 | -43.4% | 4,172 | -33.4% | 0.00% | -66.7% |
| Q2 2020 | $304,000 | +16.5% | 6,268 | +1.4% | 0.00% | 0.0% |
| Q1 2020 | $261,000 | +0.4% | 6,182 | +1.8% | 0.00% | +50.0% |
| Q4 2019 | $260,000 | +170.8% | 6,072 | +127.4% | 0.00% | +100.0% |
| Q3 2019 | $96,000 | +43.3% | 2,670 | +6.8% | 0.00% | 0.0% |
| Q2 2019 | $67,000 | 0.0% | 2,500 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $67,000 | +67.5% | 2,500 | 0.0% | 0.00% | – |
| Q4 2018 | $40,000 | -23.1% | 2,500 | 0.0% | 0.00% | – |
| Q3 2018 | $52,000 | -14.8% | 2,500 | -37.5% | 0.00% | -100.0% |
| Q2 2018 | $61,000 | +96.8% | 4,000 | +185.7% | 0.00% | – |
| Q1 2018 | $31,000 | -26.2% | 1,400 | 0.0% | 0.00% | – |
| Q4 2017 | $42,000 | -41.7% | 1,400 | -26.7% | 0.00% | -100.0% |
| Q3 2017 | $72,000 | +35.8% | 1,910 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $53,000 | -65.8% | 1,910 | -57.6% | 0.00% | -50.0% |
| Q1 2017 | $155,000 | +34.8% | 4,510 | +12.8% | 0.00% | +100.0% |
| Q4 2016 | $115,000 | +259.4% | 4,000 | +300.0% | 0.00% | – |
| Q3 2016 | $32,000 | 0.0% | 1,000 | 0.0% | 0.00% | – |
| Q2 2016 | $32,000 | +14.3% | 1,000 | 0.0% | 0.00% | – |
| Q1 2016 | $28,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |